Eli Lilly and Company announces that ixekizumab (Taltz®) has been recommended by NICE for use as a treatment option for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs). NICE issued its final guidance on the use of ixekizumab today.
The NICE guidance states that ixekizumab alone, or with methotrexate, is recommended for treating active psoriatic arthritis in adults. This is for patients who have peripheral arthritis with three or more tender joints, if the patient has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks.
“Up to 30% of people with psoriasis will develop psoriatic arthritis, a severe form that causes swollen, stiff and painful joints.”
Ixekizumab is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor, a protein which plays a key role in psoriatic arthritis. Ixekizumab was granted EU marketing authorisation (MA) for Taltz® (ixekizumab) in January 2018, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
The European Commission Marketing Authorisation for ixekizumab in PsA was based on findings from a Phase 3 clinical trial program. The efficacy and safety of ixekizumab was determined from findings from two randomized, double-blind, placebo-controlled Phase 3 studies– SPIRIT-P1 and SPIRIT-P2 – which included 780 adult patients with active PsA.
Dr. Arash Tahbaz, Senior Medical Director, Eli Lilly and Company, UK and Northern Europe said, “Up to 30 per cent of people with psoriasis will also develop psoriatic arthritis, a severe form of inflammatory arthritis that can cause swollen, stiff and painful joints. It can reduce physical function and lead to a reduction in quality of life so we are pleased that NICE is able to recommend this new treatment option.”